Dopamine and Serotonin in Mood and Psychosis Video

Dysregulation of the neurotransmitters dopamine and serotonin may be associated with neuropsychiatric disorders such as schizophrenia, depression, and bipolar disorder. Targeting dopamine (D2) and serotonin (5-HT1A, 5-HT2A) receptors may help address symptoms of neuropsychiatric conditions such as depression, bipolar disorder, and schizophrenia.


Dopamine and serotonin in mood and psychosis. Dopamine and serotonin are neurotransmitters thought to be involved in mood, psychosis, memory, and cognition. Dysregulations of these neurotransmitters may be associated with neuropsychiatric disorders, including schizophrenia, depression, and bipolar disorder. While these neurotransmitters act on a variety of receptors, dopamine D2 receptors in the striatum and serotonin 5-HT1A and 5-HT2A receptors in the prefrontal cortex may play an important and interconnected role in mood and psychosis.

Antagonism of dopamine D2 receptors may help address symptoms of neuropsychiatric disorders. However, this approach can be associated with adverse effects. Dual antagonism of dopamine D2 and serotonin 5HT2A receptors may increase dopamine release in the striatum, resulting in competition for the D2 receptor. This may reduce dopamine D2 receptor antagonism, and may theoretically mediate adverse effects, such as extrapyramidal symptoms.

Additionally, activation of the serotonin 5HT1A receptor by a partial or full agonism increases serotonin transmission. This may theoretically be associated with antidepressant effects, while also helping mediate extrapyramidal side effects. Thus, antagonizing dopamine D2 and serotonin 5-HT2A receptors, and also activating serotonin 5 -HT1A receptors, is hypothesized to help mitigate adverse effects and may reduce symptoms of depression. Targeting serotonin and dopamine pathways are thought to play a role in the management of bipolar disorder, depression, and schizophrenia. 


  1. Stiedl O, Pappa, E, Konradsson-Geuken A, Ogren S. The role of the serotonin receptor subtypes 5HT1a and 5HT7 and its interaction in emotional learning and memory. Front Pharmacol. 2015;8(162). doi:10.3389/fphar.2015.00162
  2. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed. Cambridge University Press; 2013.
  3. Berk M, Dodd S, Kauer-Sant'anna M, et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl. 2007;116(434):41-49. doi:10.1111/j.1600-0447.2007.01058.x
  4. Ashok AH, Marques TR, Jauhar S, et al. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry. 2017;22(5):666-679. doi:10.1038/mp.2017.16
  5. Celada P, Puig MV, Amargós-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. 2004;29(4):252–265.
  6. Brunton L, Chabner B, Knollman B. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. McGraw Hill; 2011.
  7. Lacroix LP, Hows MEP, Shah AJ, Hagan JJ, Heidbreder CA. Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology. 2003;28(5):839-849. doi:10.1038/sj.npp.1300114
  8. Mineur YS, Einstein EB, Bentham MP, et al. Expression of the 5-HT1A serotonin receptor in the hippocampus is required for social stress resilience and the antidepressant-like effects induced by the nicotinic partial agonist cytisine. Neuropsychopharmacology. 2015;40(4):938-946. doi:10.1038/npp.2014.269
  9. Assié MB, Cosi C, Koek W. Eur J Pharmacol. 1997;334(2-3):141-147. doi: 10.1016/s0014-2999(97)01207-7 

This resource is intended for educational purposes only and is intended for US healthcare professionals. Healthcare professionals should use independent medical judgment. All decisions regarding patient care must be handled by a healthcare professional and be made based on the unique needs of each patient. 

ABBV-US-01602-MC, Version 1.0
Approved 05/2024
AbbVie Medical Affairs

Welcome To NP Psych Navigator

This website is intended for healthcare professionals inside the United States.
Please confirm that you are a healthcare professional inside the US.

No, I am not US Healthcare professional

You are now leaving NP Psych Navigator

Links to sites outside of NP Psych Navigator are provided as a resource to the viewer. AbbVie Inc accepts no responsibility for the content of non-AbbVie linked sites.

Redirect to:

Please to bookmark content